P123 | IBRUTINIB AND VENETOCLAX IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS OUTSIDE CLINICAL TRIALS: A SINGLE-CENTER REAL-WORLD EXPERIENCE

Introduction: The combination of ibrutinib, a Bruton's tyrosine kinase inhibitor, and venetoclax, a BCL-2 inhibitor, has shown synergistic efficacy in chronic lymphocytic leukemia (CLL). Pivotal trials like CAPTIVATE and GLOW report high rates of complete remission (CR) and undetectable minimal res...

全面介紹

書目詳細資料

Principais autores:	A. Tomasso, I. Innocenti *, L. Stirparo *, A. Fresa, A. Mosca, F. Iadevaia, T. Quaranta, F. Guglielmi, F. Autore, L. Laurenti
格式:	Artigo
語言:	Inglês
出版:	Ferrata Storti Foundation 2025-09-01
叢編:	Haematologica
在線閱讀:	https://haematologica.org/article/view/12420
標簽:	添加標簽 沒有標簽, 成為第一個標記此記錄!